scholarly journals Synchronous Occurrence of Hodgkin’s Lymphoma and Lung Cancer

2021 ◽  
Vol 8 (3) ◽  
Author(s):  
Erdem R ◽  
◽  
Aykas F ◽  
Gocer M ◽  
Ozen IN ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Nodes ◽  
Hodgkin Lymphoma ◽  
Age Of Onset ◽  
Second Primary ◽  
Lung Pathology ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Pet Ct ◽  
The Right

Hodgkin lymphoma is an uncommon neoplasm that characterized young age of onset, Hodgkin and Reed-Sternberg (HRS) cells derived from B-lymphocytes and a high cure rate, even when the patient presents with advanced metastatic spread. Lung cancer is the most common cancer worldwide and is still responsible for the most cancer deaths. We present an extremely rare case of coexisting Hodgkin lymphoma and lung cancer in a 67-year-old male patient. He initially presented with chest pain. Pet/ct revealed mass in the right lung and lymph nodes in the neck. Biopsy from the premaxillary lymph node was compatible with classical Hodgkin lymphoma. In terms of second primary malignancy, a biopsy was also performed from the mass in the right lung. Pathology showed a pulmonary adenocarcinoma and a right upper lobectomy was then performed. This patient was treated with gemcitabine plus docetaxel for lung cancer. At the end of treatment pet/ct was complete response including lymph nodes in the neck. Therefore, we did not give any treatment for Hodgkin lymphoma. The patient is still being followed up in remission.

The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study

2021 ◽  
Author(s):  
Jia Hong ◽  
Rongrong Wei ◽  
Chuang Nie ◽  
Anastasiia Leonteva ◽  
Xu Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cox Regression ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Risk Models ◽  
Primary Malignancy ◽  
Population Based Study ◽  
Competing Risk Models

Aim: To assess and predict risk and prognosis of lung cancer (LC) patients with second primary malignancy (SPM). Methods: LC patients diagnosed from 1992 to 2016 were obtained through the Surveillance, Epidemiology, and End Results database. Standardized incidence ratios were calculated to evaluate SPM risk. Cox regression and competing risk models were applied to assess the factors associated with overall survival, SPM development and LC-specific survival. Nomograms were built to predict SPM probability and overall survival. Results & conclusion: LC patients remain at higher risk of SPM even though the incidence declines. Patients with SPM have a better prognosis than patients without SPM. The consistency indexes for nomograms of SPM probability and overall survival are 0.605 (95% CI: 0.598–0.611) and 0.644 (95% CI: 0.638–0.650), respectively.

scholarly journals Mortality of lung cancer as a second primary malignancy: A population‐based cohort study

2019 ◽  
Vol 8 (6) ◽  
pp. 3269-3277
Author(s):  
Lei Deng ◽  
Hrönn Harðardottír ◽  
Huan Song ◽  
Zhengrui Xiao ◽  
Changchuan Jiang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

scholarly journals The risk of second primary malignancy in patients with stage Ia non-small cell lung cancer: a U.S. population-based study

2017 ◽  
Vol 57 (2) ◽  
pp. 239-243 ◽  
Author(s):  
Amit Khanal ◽  
Bilal Haider Lashari ◽  
Sreechandralekha Kruthiventi ◽  
Lubina Arjyal ◽  
Amir Bista ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Population Based ◽  
Small Cell ◽  
Second Primary ◽  
Small Cell Lung ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Population Based Study ◽  
Stage Ia

Trend of second primary malignancy in Hodgkin lymphoma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18713-e18713
Author(s):  
Mahesh Nepal ◽  
Ranju Kunwor ◽  
Dominic Ho ◽  
Krishna Bilas Ghimire
Keyword(s):  
Hodgkin Lymphoma ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

Prognosis of lung cancer as a second primary malignancy among cancer survivors: A population-based cohort study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21005-e21005
Author(s):  
Lei Deng ◽  
Zhengrui Xiao ◽  
Changchuan Jiang ◽  
Qian Wang ◽  
Haiying Cheng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Cancer Survivors ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study

2011 ◽  
Vol 29 (31) ◽  
pp. 4096-4104 ◽  
Author(s):  
Anthony J. Swerdlow ◽  
Craig D. Higgins ◽  
Paul Smith ◽  
David Cunningham ◽  
Barry W. Hancock ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Second Primary ◽  
Second Cancer ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Second Cancer Risk

Purpose We investigated the long-term risk of second primary malignancy after chemotherapy for Hodgkin's lymphoma (HL) in a much larger cohort than any yet published, to our knowledge. Patients and Methods We followed 5,798 patients with HL treated with chemotherapy in Britain from 1963 to 2001—of whom 3,432 also received radiotherapy—to assess second primary malignancy risks compared with general population-based expectations. Results Second malignancies occurred in 459 cohort members. Relative risk (RR) of second cancer was raised after chemotherapy alone (RR, 2.0; 95% CI, 1.7 to 2.4) but was much lower than after combined modalities (RR, 3.9; 95% CI, 3.5 to 4.4). After chemotherapy alone, there were significantly raised risks of lung cancer, non-HL, and leukemia, each contributing approximately equal absolute excess risk. After combined modalities, there were raised risks of these and several other cancers. Second cancer risk peaked 5 to 9 years after chemotherapy alone, but it remained raised for 25 years and longer after combined modalities. Risk was raised after each common chemotherapy regimen except, based on limited numbers and follow-up, adriamycin, bleomycin, vinblastine, and dacarbazine. The age and time-course relations of lung cancer differed between chemotherapy alone and combined modalities. Conclusion Although chemotherapy alone leads to raised risk of second malignancy, this risk is lower and affects fewer anatomic sites than that after combined modalities, and it is slight if at all after 15 years follow-up. The mechanism of lung cancer etiology may differ between chemotherapy and radiotherapy.

scholarly journals Human Papilloma Virus-Related Metachronous Tracheal Cancer in a Patient with Tonsillar Cancer

2021 ◽  
Vol 64 (4) ◽  
pp. 258-262
Author(s):  
Yun Ji Lee ◽  
Min Ki Lee ◽  
Seung Won Lee ◽  
Ki Nam Park
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papilloma Virus ◽  
Cell Carcinoma ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Papilloma Virus ◽  
Tonsillar Cancer ◽  
The Right ◽  
Cancer Lesion

Second primary malignancy (SPM) is a well-known cause of death in head and neck cancers. Recently, with reports of many incidences of human papilloma virus (HPV) associated SPM, the disease has been widely investigated. We report a HPV-positive tracheal cancer in a 49-yearold male who had been diagnosed with HPV-positive squamous cell carcinoma of the right tonsil within intervals of two years. In this case, the metachronous tracheal cancer lesion as well as the primary tonsillar cancer showed the same subtype HPV-16.

Sign in / Sign up

Export Citation Format

Share Document